Equillium (NASDAQ:EQ) Releases Quarterly Earnings Results

Equillium (NASDAQ:EQ) posted its earnings results on Thursday. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01, FiscalAI reports.

Equillium Stock Performance

EQ stock traded down $0.01 during mid-day trading on Friday, hitting $1.31. The company had a trading volume of 56,490 shares, compared to its average volume of 598,462. The firm has a market cap of $83.38 million, a PE ratio of -6.57 and a beta of 2.08. Equillium has a 12 month low of $0.76 and a 12 month high of $3.54. The stock’s fifty day moving average price is $1.61 and its two-hundred day moving average price is $2.08.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Equillium in a research report on Monday, September 21st. Jefferies Financial Group set a $4.00 price target on Equillium and gave the stock a “buy” rating in a report on Friday. Wall Street Zen cut Equillium from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. Leerink Partners started coverage on Equillium in a research report on Monday, October 12th. They issued an “outperform” rating and a $6.00 price objective on the stock. Finally, Zacks Research upgraded Equillium from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Equillium presently has an average rating of “Moderate Buy” and an average price target of $7.12.

About Equillium

Equillium is a biotechnology company focused on developing medicines that target immune pathways involved in autoimmune and inflammatory diseases. Its research has centered on treatments for conditions with significant unmet medical needs. The company’s leading program has been itolizumab, a monoclonal antibody that targets CD6, an immune-cell protein. Equillium obtained development and commercialization rights to itolizumab from India-based Biocon for several markets, including the United States, Canada, Australia and New Zealand.